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Abstract
Amplification and over expression of erbB2/neu proto-oncogene is observed in 20–30% human 
breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic 
activating mutations within erbB2 in human breast cancers are rare. However, we have previously 
reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred 
to as ErbB2ΔEx16), results in oncogenic activation of erbB2 due to constitutive dimerization of 
the ErbB2 receptor. Here, we demonstrate that the ErbB2ΔEx16 is a major oncogenic driver in 
breast cancer that constitutively signals from the cell surface. We further show that inducible 
expression of the ErbB2Ex16 variant in mammary gland of transgenic mice results in the rapid 
development of metastatic multifocal mammary tumors. Genetic and biochemical characterization 
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of the ErbB2ΔEx16 derived mammary tumors exhibit several unique features that distinguish it 
from the conventional ErbB2 models expressing the erbB2 proto-oncogene in mammary 
epithelium. Unlike the wild-type ErbB2 derived tumors that express luminal keratins, 
ErbB2ΔEx16 derived tumors exhibit high degree of intra-tumoral heterogeneity co-expressing 
both basal and luminal keratins. Consistent with these distinct pathological features, the 
ErbB2ΔEx16 tumors exhibited distinct signaling and gene expression profiles that correlated with 
activation of number of key transcription factors implicated in breast cancer metastasis and cancer 
stem cell renewal.
Keywords
ErbB2; breast cancer; mouse model; splice variant
Introduction
Amplification and elevated expression of the erbB2 proto-oncogene is observed in 20 to 
30% of human breast cancers and is inversely correlated with the survival of the 
patient 3, 39, 40. Direct evidence supporting a role for ErbB2 in mammary tumorigenesis 
derives from studies with transgenic mice expressing the erbB2 proto-oncogene under the 
transcriptional control of the mouse mammary tumor virus (MMTV) promoter/enhancer. 
Mammary-epithelial expression of erbB2 oncogene results in the rapid induction of 
multifocal mammary tumors 20, 31. By contrast, mammary epithelial expression of the proto-
oncogenic form of ErbB2 (herein referred too as wild-type ErbB2) resulted in induction of 
focal mammary tumors after a long latency period 19. Tumor progression in these strains is 
associated with the activation of the ErbB2 tyrosine kinase activity due to the occurrence of 
somatic activating mutations in the transgene in a majority of the mammary tumors 
analyzed 7, 19, 36, 37. Significantly these mutations are confined to a cysteine rich region of 
the receptor located in a juxtatransmembrane domain and are comprised of either deletion or 
insertion of single cysteine residues. Further genetic and biochemical analyses has revealed 
that these cysteine alterations promote the formation intermolecular cysteine bridges 
between ErbB2 monomers, resulting in constitutive receptor dimerization and activation 37.
Although comparable somatic mutations in erbB2 have not been detected in human breast 
cancer, several studies have reported the expression of an alternatively spliced erbB2 isoform 
(ErbB2ΔEx16) that carries a 16 amino acid in-frame deletion in the juxtatransmembrane 
domain that closely mimics the sporadic erbB2 transgene mutations observed in the 
transgenic mice expressing the ErbB2 proto-oncogene 24, 38. Like sporadic transgene 
mutations, this erbB2 splice variant is constitutively active due to its capacity to form 
disulfide-bonded dimers 38. In addition to playing an important role in the oncogenic 
activation of ErbB2 receptor, it has been recently reported that the ErbB2ΔEx16 isoform is 
the principle target of the anti-ErbB2 therapeutic monoclonal Trastuzumab 1, 5.
To further validate the biological significance of the ErbB2ΔEx16 variant in mammary 
epithelium, we established a transgenic mouse model that expresses the ErbB2ΔEx16 variant 
in an inducible fashion in the mammary epithelium. In contrast to the transgenic mice 
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expressing the wild-type ErbB2 receptor in the mammary epithelium that developed focal 
mammary tumors after a long latency period, the ErbB2ΔEx16 strains rapidly developed 
multifocal mammary tumors that frequently metastasized to the lung. Remarkably, in 
contrast to the ErbB2 tumors that uniformly expressed the luminal keratin 8 marker, the 
ErbB2ΔEx16 derived tumors exhibited a high degree intra-tumoral heterogeneity expressing 
both luminal and basal keratins. Consistent with basal origin of these tumors, gene 
expression analyses revealed that in contrast to luminal pattern for ErbB2, the ErbB2ΔEx16 
derived tumors possessed many features of basal breast cancer. Molecular and genetic 
analyses of these tumors further showed that basal molecular phenotype was due to selective 
signaling of the c-Src family and p38 kinases by the ErbB2ΔEx16 variant that in-turn 
resulted in activation of the Smad2, HIF1α, Stat3 and YB-1 transcriptional networks. Taken 
together, these observations suggest that the ErbB2ΔEx16 isoform possesses distinct 
signaling and cellular localization processes that may impact on its role in mammary tumor 
progression.
Results
The ErbB2ΔEx16 isoform is expressed at different levels in a number of ErbB2 positive cell 
lines and confers transforming activity in vivo
To confirm the prevalence of the ErbB2ΔEx16 isoform in ErbB2 positive category of breast 
cancer, we used a an RNA-seq approach to simultaneously measure the abundance of the 
ErbB2ΔEx16 compared to wild type transcript ErbB2 transcript in a collection of established 
breast cancer cell lines representing the different breast cancer subtypes 32 (Fig. 1A). The 
results revealed that the abundance of the ErbB2ΔEx16 isoform varied considerably with the 
different ErbB2 positive cells lines. Although the low levels of ErbB2 spliced form were 
detected in the SKBR3 (1.8% of the total ErbB2 transcript), relatively high levels of the 
ErbB2ΔEx16 were seen in the ZR7530 cells (12% of the total ErbB2 transcript) (Fig. 1B). 
Other ErbB2 cell lines maintained a modest level of the spliced variant (4–5% of total 
ErbB2). Although the proportion of ErbB2ΔEx16 variant varied in ErbB2 positive lines, due 
to amplification of ErbB2, the absolute levels of the ErbB2ΔEx16 variant were high by 
comparison to other breast cancer cell lines representing the other breast cancer subtypes 
(Fig. 1C).
Interestingly, the expression of the ErbB2ΔEx16 form was not restricted to tumor cells. 
Using RT-PCR that allowed the simultaneous measurement of wild-type ErbB2 and 
ErbB2ΔEx16 transcripts, we showed that the ErbB2ΔEx16 variant could be detected at 
variable levels (2–10% of total ErbB2 transcript) in a variety of normal human tissues (Fig. 
S1). Together these observations indicate that both wild-type ErbB2 and ErbB2ΔEx16 
transcripts are expressed in both normal and malignant tumor samples and that breast cell 
lines possessing amplified ErbB2 possessed particularly elevated levels of the ErbB2ΔEx16 
variant.
Although these observations suggest that the ErbB2ΔEx16 transcript is expressed at elevated 
levels in ErbB2 amplified breast cancer cell lines, the biological significance of these 
observations was unclear. To directly test the transforming properties of this variant, we 
established independent clones of immortalized NMuMG mammary cells that expressed 
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either constitutively active rat ErbB2 (NeuNT) 45, wild-type human ErbB2 or the human 
ErbB2ΔEx16 variant at comparable levels (Fig. S2A). To evaluate whether cells expressing 
the ErbB2 variants exhibited differential tumorigenic potential, mammary cells derived from 
two independent clones expressing either wild-type ErbB2, activated ErbB2 (NeuNT) or 
ErbB2ΔEx16 were injected orthotopically into immunodeficient recipient mice and their 
growth monitored (Fig. S2B). In contrast to the rapid onset of tumors seen in both clones 
expressing NeuNT and the ErbB2ΔEx16, 2 independent clones of cells expressing the wild-
type form of ErbB2 failed to form tumors (Fig. S2B). These observations argue that unlike 
the ErbB2ΔEx16 and activated forms of ErbB2 (Neu-NT), elevated expression of wild-type 
ErbB2 is not sufficient to convert these immortalized cells to the malignant phenotype.
While wild-type ErbB2 appears to be incapable of transforming immortalized epithelial 
cells, an outstanding question is whether this isoform is capable of maintaining a 
tumorigenic state. In order to test this, NMuMG cells were used to generate cell lines 
expressing a doxycycline-inducible ErbB2ΔEx16, isolating cells with tightly regulated 
induction (Fig 2B). In the presence of doxycycline, robust ErbB2ΔEx16 protein expression 
is observed as quickly as 24 hours after in vitro doxycycline administration (Fig 2A). These 
cells were subsequently engineered to express wild-type ErbB2 as well, which were selected 
using FACS in the absence to doxycycline, in order to sort cells by robust wild-type ErbB2 
expression. Cells were injected orthotopically into athymic nude mice, and the mice were 
treated with 2mg/ml doxycycline in the drinking water. Consistent with previous results, 
ErbB2ΔEx16 induction drives rapid transformation and tumor outgrowth (Fig 2C). However, 
when doxycycline is withdrawn, the tumors fail to express ErbB2ΔEx16 but retain robust 
expression of wild-type ErbB2 (Fig 2B), leading to rapid regression of the established 
mammary tumors (Fig. 2D). These observations demonstrate that expression of wild-type 
ErbB2 is insufficient to maintain a tumorigenic state in the absence of ErbB2ΔEx16 
expression and indicate that the ErbB2ΔEx16 isoform and indicate that the ErbB2ΔEx16 
isoform is a major oncogenic driver.
To determine whether the differential transforming activity of the ErbB2ΔEx16 variant 
involved altered receptor recycling, we performed immunofluorescence staining on cells 
expressing the different ErbB2 receptors with antibodies directed towards ErbB2 and the 
early endosome marker EAA1 (Fig. 3A). Cells were treated with cycloheximide in serum-
free medium for one hour, followed by one hour in complete medium at 4°C. To permit 
receptor internalization, cells were warmed to 37°C with fresh complete medium for 15 
minutes. Examination of NeuNT expressing cells revealed that ErbB2 and EAA1 were co-
localized in the early endosome, indicating rapid down-regulation of ErbB2 from the cell 
surface (Fig. 3A). In contrast to these observations, the ErbB2ΔEx16 variant could not be 
detected in the endosomal compartment.
To confirm that lack of detectable ErbB2ΔEx16 receptor in the endosomal compartment was 
due to defect in down-regulation from the cell surface, we performed a biotin labeling of cell 
surface proteins and measured the percentage of internalized ErbB2 that was protected from 
proteolytic degradation (see Material and Methods). Consistent with the rapid internalization 
of NeuNT in the endosomal compartment, a significant percentage of ErbB2 was protected 
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60 minutes after shifting the cells to the permissive temperature for sorting. By contrast only 
a small proportion of the ErbB2ΔEx16 variant was internalized (Fig. 3B and 3C).
Another indication of altered trafficking for ErbB2ΔEx16 derived variant stem from the 
observation that mammary tumor cell lines derived from either transgenic mice (Fig. 4) or 
NMuMG cells expressing the ErbB2ΔEx16 isoform are resistant to the anti-ErbB2 
therapeutic T-DM1 antibody–drug conjugate whereas control cells expressing the wild-type 
ErbB2 were highly sensitive to T-DM1 (Fig. 3D and 3E). Given that T-DM1 drug delivery 
requires internalization, the inability of T-DM1 to kill these the ErbB2ΔEx16 expressing 
likely reflects it inability to be internalized 12. Collectively these observations demonstrate 
that the ErbB2ΔEx16 is primarily a cell surface receptor that is not efficiently internalized 
and also indicate that expression of the ErbB2ΔEx16 isoform may confer resistance to T-
DM1.
Mammary specific expression of the ErbB2ΔEx16 isoform results in the rapid induction of 
metastatic breast cancers
To directly evaluate the oncogenic potential of the ErbB2ΔEx16 isoform in the mammary 
epithelium, we placed the ErbB2ΔEx16 under the transcriptional control of the tetracycline 
response element and crossed these strains of FVB mice to a separate FVB strain expressing 
the Reverse Tetracycline Trans activator (rtTA) under the transcriptional control of the 
mouse mammary tumor virus promoter (MMTV) 29. To facilitate detection of transgene 
expressers, we placed an IRES EGFP expression cassette downstream of the ErbB2ΔEx16 
cDNA (Fig. 4A). In this manner, we can induce expression of the ErbB2ΔEx16 in the 
mammary epithelium by the addition of doxycycline to the drinking water. Of the initial 7 
independent founder lines, 2 independent the founder strains could be induced to express 
elevated levels of the ErbB2ΔEx16 isoform upon doxycycline administration (Fig. S3A and 
S3B). Using RT-PCR analyses, we show that ErbB2ΔEx16 expression is primarily restricted 
to the mammary and salivary glands (Fig S4).
To further characterize the kinetics of tumor onset in the inducible ErbB2ΔEx16, we 
generated cohorts of female mice from two of these independent strains and monitored 
tumor induction following addition of doxycycline to drinking water. Groups were 
unblinded throughout the study, and a target sample size of 20 per group was chosen to 
ensure sufficient statistical power. The results revealed that in contrast to MMTV/ErbB2 
strain that developed focal mammary tumors after long latency period (T50=280 days) 15, 
both inducible ErbB2ΔEx16 strains rapidly induced multifocal mammary tumors with an 
extremely short latency period (T50=10 and 28 days) (Fig. 4B). Additionally, ErbB2ΔEx16 
tumors frequently gave rise to metastatic lesions in the lung in a majority of tumor bearing 
animals (Fig 4C–D).
Histological analyses of these tumors revealed that that the ErbB2ΔEx16 possessed tumor 
pathology that is distinct from those expressing the erbB2 proto-oncogene (Fig. 5A and 5C). 
Using trichrome staining, which stains for collagen deposition, we confirmed that 
ErbB2ΔEx16 derived tumors possess much higher levels of matrix deposition than the 
comparable ErbB2 tumors (Fig. 5B and 5D).
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To further evaluate whether the observed pathological differences between the two ErbB2 
tumor models was due to different cellular origin, we next stained both full length and the 
ErbB2ΔEx16 derived tumors with either luminal (cytokeratin 8) or basal keratin (cytokeratin 
14, 6 and 5) markers. In contrast to tumors expressing full length ErbB2 that were uniformly 
positive for Keratin 8 marker and negative for any of the basal keratin markers, the 
ErbB2ΔEx16 derived tumors stained positive for both luminal and basal keratins (Fig. S5A). 
Indeed, co-staining with different keratin markers revealed a diversity of cells that co-
expressed both basal and luminal keratin markers. (Fig. S5B). Collectively these 
observations argue that in contrast to ErbB2 derived tumors, mammary epithelial expression 
of ErbB2ΔEx16 results in rapid induction metastatic mammary tumors that possess a high 
degree of intra-tumoral heterogeneity.
To further establish the critical importance of the ErbB2ΔEx16 as major oncogenic driver in 
mammary tumorigenesis, we next determined whether withdrawal of doxycycline from the 
drinking water in ErbB2ΔEx16 tumor bearing mice would result in tumor regression. The 
results showed that removal of doxycycline from tumor-bearing animals resulted in rapid 
regression of the ErbB2ΔEx16 derived tumors. However after a variable tumor-free period, 
focal mammary tumors reappeared (Fig. S6A). Molecular and pathological analyses of these 
recurrent tumors revealed that exhibited EMT phenotype (Fig. S6C) that was further 
correlated with reduced expression of the epithelial marker E-Cadherin and complete loss of 
the ErbB2ΔEx16 transgene expression (Fig. S6B). Thus like our previous cell culture data 
(Fig. 2), these observations indicate that sustained expression of the ErbB2ΔEx16 is required 
to maintain the transformed state.
The ErbB2ΔEx16 derived tumors exhibit unique signaling and transcriptional profiles due 
to activation of transcription factor network
To further elucidate the molecular basis for the potent transforming ability of the 
ErbB2ΔEx16 isoform we performed both RPPA and immunoblot analyses on a number of 
downstream signaling pathways. Despite the constitutive dimerization of the ErbB2ΔEx16 
receptor 38, the levels of tyrosine phosphorylated ErbB2, EGFR and ErbB3 were impaired 
by comparison ErbB2 tumors (Fig. 6A). Conversely, the ErbB2ΔEx16 derived tumors 
exhibited a profound activation of p38 and c-Src family kinases compared to the tumors 
expressing the ErbB2 receptor (Fig. 6B). Another important set of phosphorylated proteins 
that were clearly activated by RPPA as measured by the phosphorylation status in the 
ErbB2ΔEx16 derived tumors were a number of transcription factors, including Stat-3, YB-1, 
Smad-2 and HIF1α (Fig. S7). To confirm that activation status of this transcription factor 
network in the ErbB2ΔEx16 class of mammary tumors, we performed immunoblot analyses 
with phospho-specific antibodies directed against each of these transcription factors. 
Consistent with RPPA analyses, the results showed that although there was no absolute 
increase in the levels in these transcription factors, the ErbB2ΔEx16 derived tumors 
exhibited a dramatic elevation in activation status of these key transcription factors (Fig. 
6C).
The observations outlined above indicate that the ErbB2ΔEx16 derived tumors have 
pathological and molecular features that are distinct from tumors induced by the ErbB2 
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receptor. To further explore the molecular basis for the striking differences between these 
closely related ErbB2 receptors, we performed gene expression profiling on 8 independent 
tumors from either the wild-type ErbB2 or the ErbB2ΔEx16 strains using the Agilent 
platform. Consistent with the molecular and pathological analyses, unsupervised hierarchical 
clustering of gene expression profiles revealed that the ErbB2Δ16 tumors co-clustered and 
could be readily distinguished from their ErbB2 counterparts (Fig. 6D). Given that our 
RPPA data indicated that ErbB2ΔEx16 selectively activated Stat3, Smad2 and HIF-1α 
transcription factors, we next evaluated whether differential gene expression profiles 
between two ErbB2 tumor subtypes could be due to selective activation of this 
transcriptional factor network. To accomplish this, we determined whether known target 
genes of these transcription factors were selectively up-regulated in the ErbB2ΔEx16 derived 
tumors. The results of these analyses confirmed that differential gene expression profile 
exhibited by the ErbB2ΔEx16 derived tumors can in part, be accounted for by activation of 
this transcriptional network (Fig. 7A). Target genes downstream of Smad-2 (p=0.0019), 
HIF1α (p=0.014) and Stat3 (p=0.008) were significantly enriched in ErbB2ΔEx16 samples 
(Fig. 7B, 7C, and 7D). Notably, expression of Stat3 target genes such interferon γ and 
Cxcl10 that have implicated in regulation of tumor immune microenvironment were 
dramatically up-regulated in the ErbB2ΔEx16 derived tumors. Similarly, selective up-
regulation of Smad-2 targets such TGF β superfamily was also observed in the ErbB2ΔEx16 
derived tumor setting (Fig. 7A). In addition, transcription factors Snail1 and Twist1 that are 
also targets of Smad-2 and HIF1α in ErbB2ΔEx16 tumors. Interestingly, these latter 
transcription factors are thought to play a critical role in EMT process 14. Collectively, these 
observations indicate that the ErbB2ΔEx16 derived tumors possess transcriptional signature 
associated with invasive breast cancers.
Discussion
In this study, we demonstrate that the oncogenic ErbB2ΔEx16 variant is expressed at 
appreciable levels in a number of ErbB2 expressing breast cancer cell lines. Additionally, we 
show that the ErbB2ΔEx16 expression is both sufficient and necessary for the maintenance 
of the transformed phenotype (Fig. 2 and Fig. S6). Specifically, we demonstrate that in 
contrast to another oncogenic ErbB2 mutant (NeuNT), the ErbB2ΔEx16 isoform is 
constitutively localized to the plasma membrane compartment (Fig. 3). Consistent with the 
unique properties of the ErbB2ΔEx16, mammary specific expression of the ErbB2ΔEx16 
resulted in rapid induction of multifocal metastatic mammary tumors that possessed 
molecular and pathological features that were distinct from the conventional MMTV ErbB2 
models. These features include high levels of intra-tumoral heterogeneity that is 
characterized by co-expression of both luminal and basal keratins and is reflected at the 
molecular level by a distinct gene expression profile (Figs. 4–7).
Although a number of studies have detected the presence of the ErbB2ΔEx16 variant in both 
established breast cancer cell lines and primary breast cancers (Fig. 1) 1, 5, 24, 38, the precise 
role of this variant in ErbB2-induced tumor progression was unclear. Using NMuMG 
immortalized mammary epithelial cell model, we demonstrate that elevated expression of 
wild-type ErbB2 is not sufficient to drive morphological transformation of this immortalized 
mammary epithelial cell line (Fig. S2). By contrast, expression of the activated ErbB2 (NT 
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mutation) or the ErbB2ΔEx16 form was sufficient to drive the tumorigenic conversion of 
NMuMG cells (Fig. S2). Furthermore, expression of wild-type ErbB2 in the context of an 
ErbB2ΔEx16-driven tumor is incapable of maintaining transformation following loss of 
ErbB2ΔEx16 expression (Fig. 2). These observations indicate that at least in this 
immortalized cell system, the ErbB2ΔEx16 is the major oncogenic driver.
The potent transforming property of the ErbB2ΔEx16 isoform were further correlated with 
constitutive localization to the plasma membrane. By contrast, other activated versions of 
ErbB2 (NeuNT) are rapidly down-regulated from the cell surface (Fig. 3A and 3B). The 
difference in receptor trafficking in ErbB2ΔEx16 tumors may account for the distinct 
signaling output from the ErbB2ΔEx16 receptor. In this regard, it has been reported that the 
ErbB2ΔEx16 variant is specifically associated within a membrane compartment harboring c-
Src 28. Another important consequence of the differential trafficking properties of the 
ErbB2ΔEx16 variant, is that tumor cells expressing this variant are highly resistant to T-
DM1 (Fig. 3C and 3D). Because the biological activity of Trastuzumab-drug conjugate is 
dependent on its ability to be internalized to release the drug toxin 12, the inability T-DM1 to 
kill the ErbB2ΔEx16 variant expressing tumor cells reflects its inability to be efficient 
internalized. These data contrast with a recent report indicating that Trastuzumab can 
effectively eliminate ErbB2ΔEx16 expressing tumors in vivo 5. The difference between the 
in vitro resistance phenotype we observed (Fig. 3) and the in vivo sensitivity may reflect the 
importance of the Antibody Directed Cellular Cytotoxicity (ADCC) in T-DM1 anti-tumor 
response 11.
Consistent with the unique signaling properties of the ErbB2ΔEx16 variant, mammary 
epithelial expression of this isoform resulted in rapid induction of multifocal mammary 
tumors that frequently metastasized to the lung, whereas comparable strains expressing 
ErbB2 in the mammary gland develop focal mammary tumors only after a long onset period 
(Fig. 4). In agreement with these observations, a transgenic line expressing the ErbB2ΔEx16 
variant with constitutive MMTV promoter rapidly developed mammary tumors 6. However, 
detailed molecular and pathological analyses of mammary tumors were not reported.
Another distinct feature of these the ErbB2ΔEx16 expressing tumors is that they have 
several unique pathological features, including major deposition of extracellular matrix 
(ECM) (Fig. 5) and co-expression of both luminal and basal keratin markers (Fig. S5). The 
dense ECM depositions observed in the ErbB2ΔEx16 derived tumors was further correlated 
with the metastatic dissemination to the lung (Fig. 5C–5D). In many respects, this ECM 
deposition phenotype resembles high breast density that is a known risk factor for 
development of breast cancer 27. Other studies have linked matrix density to directly impact 
on metastatic fate of tumor cells 10, 30
Although both of the ErbB2-driven mouse models expressed the luminal marker cytokeratin 
8 (Krt8; Fig. S5) only the ErbB2ΔEx16 derived tumors exhibited expression of basal 
cytokeratin markers such as Krt5, Krt6, and Krt14 (Fig. S5). These findings indicate that the 
ErbB2ΔEx16 derived mammary tumors exhibit a high degree of intra-tumoral heterogeneity 
comprising of mixed cell lineages, whereas MMTV wild-type ErbB2 tumors are comprised 
of a uniform luminal cell type.
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The ErbB2ΔEx16 derived tumors also exhibited a profound difference in signaling pathways 
activated compared to their full-length counterparts. Using RPPA and immunoblot analyses 
(Fig. 6, Fig. S7), we demonstrate that the ErbB2ΔEx16 derived tumors exhibit reduced 
tyrosine phosphorylation of ErbB2 and its heterodimer partners EGFR and ErbB3 (Fig. 6A) 
and elevated activation c-Src family of tyrosine kinases and activation of p38 kinase (Fig. 
6B) compared to ErbB2 derived tumors. These analyses also revealed that ErbB2ΔEx16 
dependent signaling was responsible for activation of number of key transcription factors 
including Stat3, Smad2, YB-1 and HIF1α (Fig. 6C). Activation of these transcription factor 
networks has been implicated in regulating EMT process that is involved in breast cancer 
stem cell renewal 23, 46. Consistent with these biochemical analyses, analyses of the gene 
expression profiles of ErbB2ΔEx16 derived tumors revealed that many of the known target 
genes of this transcriptional network are selectively up-regulated in ErbB2ΔEx16 derived 
tumors (Fig. 7). Critically, comparison of the ErbB2ΔEx16 transcriptional signature to the 
human data sets revealed that they align with basal category of human breast cancers that 
have particularly bad outcome (Fig. S9).
One important set of Stat3 target genes that are up-regulated in the ErbB2ΔEx16 tumors, 
such as interferon γ and Cxcl10, are important modulators of immune micro-environment 
(Fig 7). Given that activation of Stat3 is primarily in the tumor epithelium, these Stat3 
dependent cytokines are acting in a paracrine fashion to promote immune infiltration (Fig. 
S8). In this regard, it is noteworthy that mammary tumor specific disruption of Stat3 in an 
ErbB2 model results in a decrease in infiltrating macrophages due to down-regulation of a 
number of Stat3 dependent inflammatory cytokines 34. Interestingly, the loss of an 
inflammatory tumor microenvironment is associated with a dramatic decrease in ErbB2 
dependent metastasis 34. Indeed, the increase in spontaneous metastasis observed in 
ErbB2ΔEx16 derived tumors (Fig. 4) may be due to enhanced inflammatory tumor immune 
microenvironment. In addition to modulating macrophage infiltration, our recent studies 
have indicated that epithelial activation Stat3 plays a critical role in maintaining an immune-
suppressive tumor microenvironment. For example, mammary epithelial deletion of Stat3 in 
PyV mT model results in rapid immune-mediated clearance of emerging PyV mT tumors 22. 
Collectively, these observations argue that the potent transforming properties of ErbB2Δ16 
variant is due to its impact on the tumor immune microenvironment.
Recent studies have suggested that the ErbB2ΔEx16 variant may play an important role in 
biological effects of ErBB2 targeted therapies, such as the anti-ErbB2 antibody 
Trastuzumab. In one report, mammary cell lines expressing ErbB2ΔEx16 were resistant to 
Trastuzumab treatment 28 whereas several recent publications assert that Trastuzumab 
treatment can eliminate ErbB2ΔEx16-expressing tumors. Indeed, the authors of the latter set 
of studies have argued that the ErbB2ΔEx16 variant is the primary target of 
Trastuzumab 1, 5. In light of our observations that the ErbB2ΔEx16 variant confers resistance 
to Trastuzumab based T-DM1 raise the possibility that its expression may be important 
determinant of resistance to these agents. Another interesting finding from our studies is that 
the ErbB2ΔEx16 variant is also expressed to some level in a number of normal tissue sites 
(Fig. S1) indicating a potential role in normal tissue homeostasis. In this regard, we have 
shown that mice expressing ErbB2 cDNA (hence lacking the ErbB2ΔEx16 variant) develop 
both spindle and cardiac cell dysfunction indicating that the ErbB2ΔEx16 variant may have 
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important physiological functions 2, 33. More recently, several RNA splicing factors have 
been identified that facilitate exon 16 skipping 17. Future studies directed towards 
understanding the role of the ErbB2ΔEx16 form in development and tumorigenesis will shed 
important insight into targeting this key oncogenic driver.
Materials and Methods
RNA-seq analysis of breast cancer cell lines
Whole transcriptome shotgun sequencing (RNAseq) was completed on breast cancer cell 
lines and expression analysis was performed with the ALEXA-seq software package as 
previously described 18. Briefly, this approach comprises (i) creation of a database of 
expression and alternative expression sequence ‘features’ (genes, transcripts, exons, 
junctions, boundaries, introns, and intergenic sequences) based on Ensembl gene models, (ii) 
mapping of short paired-end sequence reads to these features, (iii) identification of features 
that are expressed above background noise while taking into account locus-by-locus noise, 
(iv) identification of features that are differentially expressed in samples and (v) 
identification of the subset of differentially expressed features that correspond to alternative 
expression of mRNA isoforms. RNAseq data were available for 59 lines. An average of 71.0 
million (76bp paired-end) reads passed quality control per sample. Of these, 54.0 million 
reads mapped to the transcriptome on average, resulting in an average coverage of 48.5X 
across all known genes. Log2 transformed estimates of ErbB2 exon-level and junction-level 
expression were extracted for analysis. The abundance of ErbB2ΔEx16 was determined 
using the estimated expression of the E15:E17 junction. Full length expression was 
determined by taking the mean of E15, E16 and E17 exons and the E15:E16 and E16:E17 
junctions. Error bars represent standard deviation.
Immunoblot analysis
Flash frozen tumor tissue was disrupted by mortar and pestle in liquid nitrogen, and lysed in 
a modified Hepes lysis buffer (50mM Hepes pH 7.5 (Bioshop HEP001), 150mM NaCl 
(Biobasic SB0476), 10% Glycerol (GB0232), 0.5% NP-40 (Biobasic NDB0385), 1mM 
EDTA pH 8.0 (Biobasic EB0185), 10mM NaF (Bioshop SFL001), 1mM PMSF (Bioshop 
PMS123), 10mM β Glycerophosphate (Bioshop GYP001), 1mM Na3VO4 (Bioshop 
SOV664), 10μg/ml Aprotinin (Biobasic AD0153), 10μg/ml Leupeptin (Biobasic LDJ691). 
Lysates were quantified by Bradford assay, and reduced in SDS loading buffer with β-
mercaptoethanol (Sigma M6250). Immunoblots are representative of 3 independent 
experiments.
Antibodies
The following primary antibodies were used for immunoblotting: (Santa Cruz 
Biotechnology) ErbB3 C17 (sc-285), (Cell Signaling Technology) phospho-ErbB2 
Y1221/1222 (2249), EGFR (2232), phospho-Src Family Kinase Y416 (2101), phospho-
ErbB3 Y1289 (4791), phospho-p38 (9215), p38 T180/Y182 (9212), tubulin (2148), 
phospho-Smad2 S245/250/255 (3104), Smad2/3 (3102), HIF1α (3716), phospho-Stat3 
Y705 (9145), Stat3 (9139), phospho-YB1 S102 (2900), (Millipore) c-ErbB2 Ab-3 (OP-15), 
(BD Transduction) E-cadherin (610182), (Abcam) YB1 (12148).
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Cell surface biotinylation
Surface receptors were biotinylated with Sulfo NHS ss Biotin (Fisher-Pierce 21331) to 
monitor their rates of internalization. Control cells were either not incubated at 37°C (0 
minutes control) or incubated for 3 hours at 37°C without subsequent incubation in the 
biotin stripping buffer (total surface receptor control). Cells were lysed in PLCγ lysis buffer. 
Biotinlyated protein was precipitated from 500 g of total lysate with streptavidin-coated 
agarose beads (Pierce 20347) overnight at 4°C. The lysate was then washed and prepared for 
immunoprecipitation as described previously, and analyzed by immunoblot using 
ImageQuant TL software (GE Healthcare Biosciences). The experiment was repeated 3 
times, and representative results are shown. Error bars represent standard deviation.
RPPA of transgenic mammary tumors
Flash frozen tumor pieces were disrupted using a mortar and pestle while immersed in liquid 
nitrogen, and transferred to a 50ml conical tube. Once nitrogen has evaporated, tissue was 
lysed in NP40 Lysis buffer (50mM HEPES pH 7.5, 150mM NaCl, 10% glycerol, 1% NP-40, 
1mM EDTA, 10mM NaF, 1mM PMSF, 10mM β Glycerophosphate, 1mm Na3VO4, 10μg/ml 
aprotinin, 10μg/ml leupeptin) on ice for 10 minutes. For RPPA analysis, cellular proteins 
were denatured by 1% SDS (with β-mercaptoethanol) and diluted in five 2-fold serial 
dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial diluted lysates were 
arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 Arrayer (Aushon 
BioSystems) and subjected to RPPA as described previously 13. Analysis of the RPPA data 
was performed by pooling the sample data by genotype (n=5 for MMTV/ErbB2, n=10 for 
ErbB2ΔEx16), and statistical significance was determined by subjecting the means to an 
unpaired Student’s T-test, with a p value cut off of < 0.05. Error bars represent standard 
deviation.
Genotyping
Transgenic mice were genotyped using the following primers for MTB (Fwd 
ACCGTACTCGTCAATTCCAAGGG Rev TGCCGCCATTATTACGACAAGC), EGFP for 
ErbB2ΔE16 (Fwd CACAAGTTCAGCGTGTCC Rev TGTACAGCTCGTCCATGC), and 
MMTV-ErbB2 (Fwd CCTCCTAAAGGACCTAGAGGAAGGC, Rev 
CAAGGCCAGGAGAGGCACTGGGGAG)
Generation of transgenic mice
A DNA fragment containing the Tet-responsive promoter and erbB2ΔEx16 cDNA was 
generated by PvuII restriction digest, and sent for pronuclear injection by the McGill LSC 
Transgenic Core Facility. Putative founder lines were interbred with transgenic mice 
harboring the MMTV/rtTA transgene (MTB, a kind gift from Dr. Lewis Chodosh). Bigenic 
female mice were induced for 5 days with 2mg/ml doxycycline in their drinking water. 
Transgene expression was assessed by immunoblot analysis using the thoracic mammary 
gland, and by whole-mount EGFP and hematoxylin staining of the abdominal mammary 
gland. MMTV/ErbB2 mice were a generous gift from Genentech (Roche) 15. Female 
transgenic mice carrying the MTB and ErbB2ΔEx16 transgenes were induced at 8–10 weeks 
of age with 2mg/ml doxycycline (Wisent 450-185-EG) in the drinking water, with tumor 
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onset monitored by weekly palpation. Statistical significance was determined using a Rank 
Log (Mandel-Cox) test (n=25 for MMTV/ErbB2, n=33 for ErbB2ΔEx16).
Histological staining
Tumor pieces were fixed in 10% neutral buffered formalin for 24 hours, processed and 
embedded in paraffin at the McGill LSC Histology core facility. Sections were cut and 
stained with Harris’ Haematoxylin and Eosin, or Gomori’s trichrome Stain kit (Polysciences 
24205-1) according to manufacturer’s protocol. Images are representative of at least 10 
independent samples. For immunohistochemistry, cells were treated as described 
previously 25, using Signalstain ABC kit (Vector Laboratories PK-4000) secondary antibody, 
and Liquid DAB+ substrate chromogen system (Dako 8059S) to develop, as per 
manufacturer’s instructions. Primary antibodies were anti-keratin 14 (1:500, Covance, 
Cat#PRB-155P), anti-keratin 5 (1:500 Covance, Cat#PRB-160P), anti-keratin 6 (1:500, 
Covance, Cat#PRB-169P) anti-keratin 8/18 (1:200, Fitzgerald, Cat# RDI-PROGP11), CD3ε 
(1:200, Abcam, Ab16669), phospho-Stat3 Y705 (1:200, Cell Signaling, #9145). Stained 
sections were quantified using a nuclear staining algorithm on the Aperio Imagescope 
software. All processed samples were single-blinded for genotype during experiment and 
analysis. Statistical significance was determined by two-tailed, unpaired, Student’s T test 
(CD3ε; n=10, pStat3; n=5). Error bars represent standard deviation. For 
immunohistofluorescence, fluorescent secondary antibodies Alexa488, Alexa555, and 
Alexa647 (1:1000, Molecular Probes), and counterstained using DAPI (Sigma, 32670).
Lung metastasis
At necropsy, lung tissue was fixed and processed similarly to tumor pieces. FFPE lung 
samples were step sectioned to obtain 5 sections at 50μm intervals, and stained with Harris’ 
Haematoxylin and Eosin. Samples were blinded for genotype, and metastases were counted 
by microscopic inspection (n=18 for MMTV/ErbB2, and n=22 for ErbB2ΔEx16). Metastatic 
burden analysis was performed by first determining whether the populations presented with 
different variances using an F-test. As the variances of the two groups were found to be 
significantly different, evaluation of significance of the means was determined using an 
unpaired Welch’s T-test. Error bars represent standard deviation.
RNA extraction and microarray analysis
Total RNA from transgenic tumor samples (n=9 for MMTV/ErbB2, n=7 for ErbB2ΔEx16) 
was harvested using the RNEasy mini kit (Qiagen 74106) according to manufacturer’s 
instructions. Total RNA was quantified using a NanoDrop Spectrophotometer ND-1000 
(NanoDrop Technologies, Inc.) and its integrity was assessed using a 2100 Bioanalyzer 
(Agilent Technologies). Cyanine 3-labeled CTP cRNA was produced with 1ug of total RNA 
using the Low Input Quick Amp Labeling Kit, according to manufacturer’s instructions 
(Agilent Technologies, Inc).
The labeled cRNA was then normalized at 600ng, fragmented and hybridized on SurePrint 
G3 Mouse GE 8×60K. The arrays were incubated in an Agilent Hybridization oven at 65°C 
for 17 hours at 10 rpm. They were washed and scanned on an Agilent DNA Microarray 
Scanner C. All these steps were done according to Agilent One-Color Microarray-Based 
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Gene Expression Analysis protocol (Agilent Technologies, Inc). Data was obtained using the 
Agilent Feature Extraction software version 11.0.1.1. Using the LIMMA R package 42, 
normalization was performed through the application of background correction with the half 
setting 35, and subsequent quantile between-array normalization 41. Probe data was 
collapsed to RefSeq features by taking the median value. Unsupervised hierarchical 
clustering was accomplished through the use of Ward’s algorithm using the Pearson 
correlation distance metric applied on the features having the top 2% highest variance across 
samples. Array data from ErbB2 samples (n=9) and ErbB2ΔEx16 (n=7) samples were 
analyzed using the SAM 44 algorithm to identify significant fold changes up and down 
regulated in the ErbB2ΔEx16 samples as compared to the ErbB2 positive samples. The top 
1000 differentially regulated genes were placed into iRegulon 21 with Smad2, STAT3 and 
Hif1α to view gene interactions between differentially regulated genes and Smad2, STAT3, 
and Hif1α. Gene Set Enrichment Analysis 43 was performed to identify Smad2 and Hif1α 
gene set enrichment in the ErbB2ΔEx16 samples using genepattern. Stat3 activity was 
predicted using a gene signature approach according to previous studies4, 8, 16. Immune gene 
signature was determined by subjecting the processed gene signatures to Enrichr Gene 
Enrichment Analysis 9.
Cell culture
NMuMG (ATCC CRL1636) and SKBR3 (ATCC HTB30) cells were cultured in DMEM 
(Wisent 319-005-CL) supplemented with 10% FBS (Wisent 095-150), 10mM HEPES pH 
7.5 (Wisent 330-050-EL), 10μg/ml insulin (Wisent 511-016-UG), 100IU/ml Penicillin and 
100μg/ml Streptomycin (Wisent 450-201-EL). NMuMGErbB2wt and NMuMG-
ErbB2ΔEx16 cell lines were transfected with either pMSCVErbB2wt or pMSCV-
ErbB2ΔEx16 plasmids using Genejuice (Novagen 70967), and selected with 2μg/ml 
puromycin (Clontech 631305). NMuMG-NeuNT cells were generated as reported 
previously45. For doxycycline-inducible cell lines, prior to pMSCV transfection, NMuMG 
cells were first infected with lentivirus carrying pTIBZ-ErbB2wt or pTIBZ-ErbB2ΔEx16, 
selected in 8μg/ml Blasticidin (Thermo Fisher A1113903), induced with 10μg/ml 
doxycycline, and sorted by FACS analysis for robust ErbB2 expression. All cell lines were 
negative for mycoplasma.
RT-PCR analysis
1μg of total RNA is converted to cDNA using the NEB ProtoScript II First Strand cDNA 
Synthesis Kit (New England Biolabs E6560S). Q-PCR reactions were performed in triplicate 
using 1/10 of the RT product with the Roche LightCycler 480 SYBR Green I Master kit 
(Roche 04707516001). ErbB2ΔEx16 mRNA was detected using specific primers (Fwd 
CAGCGGTGTGAAACCTGACC, Rev TGGACGTCAGAGGGGAGTGG), normalized to 
either wild-type ErbB2 (Fwd GTGGACCTGGATGACAAGGG, Rev 
TGCTGCCGTCGCTTGATGAG) or GAPDH (Fwd GTGGTCTCCTCTGACTTCAAC Rev 
GTTGCTGTAGCCAAATTCGTTG). All samples were analyzed in triplicate with error bars 
representing standard deviation.
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Orthotopic injections
Experiments were conducted according to an approved institutional Animal Use Protocol. 
1×105 cells were injected into the left inguinal fat pad of athymic nude mice (Charles River 
Laboratories International), with mice fed 2mg/ml doxycycline in the drinking water, 
changed weekly. Tumors were monitored by weekly measurements. When tumors reached 
an approximate size of 1 cm3, doxycycline treatment was withdrawn, and tumors were 
monitored twice weekly for outgrowth. The results are representative of 3 repetitions, with 
n=5 injections per cell line.
Immunofluorescence
2.5×104 cells were seeded on coverslips and allowed to grow for 48 hours. Cells were 
incubated with 100μg/ml of cycloheximide (Sigma-Aldrich C1988-1G) in serum-free media 
for one hour. Immunofluorescence was performed as described in Marcotte et al.26 with the 
primary antibodies c-ErbB2 (1:500, DAKO A048529), and EEA1 (1:100, Santa Cruz 
sc-6415). Cells were counterstained with DAPI (Invitrogen D1306). Confocal images were 
obtained using an Axiovert 200M microscope (Carl Zeiss MicroImaging, Inc.) and analyzed 
using LSM5 Image browser (Empix Imaging). Images are representative of 3 replicates.
MTT assay
A total of 3000 cells (SKBR3) or 5000 cells (NMuMG and ErbB2ΔEx16 transgenic breast 
cancer cell lines) were plated in a final volume of 0.2 ml in 96-well flat bottom plates with 
indicated concentrations of Trastuzumab-DM1. After 3 days, 20 μl of a 5 mg/ml MTT 
solution in PBS were added to each well for 4 hours. After removal of the medium, 100 μl of 
DMSO were added to each well. The absorbance at 540 nm was determined using a Bio-Rad 
Model 680 microplate reader. At minimum, triplicate wells were assayed for each condition.
Study approval
All animal studies were carried out in accordance with the guidelines of the approved 
Animal Use Protocol by the McGill University Animal Care Committee (UACC) and the 
Canadian Council on Animal Care (CCAC).
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
RNA Seq analysis of human breast cancer cell lines. (A) ErbB2ΔEx16 is an isoform of 
ErbB2 that lacks, by alternative splicing, the 16 amino acids encoded by exon 16. (B) 
Consistent with previous findings, the ratio of ErbB2ΔEx16 transcript falls between 2–10% 
of total ErbB2 transcript across all cell line transcriptional subtypes. (C) Total levels of 
ErbB2ΔEx16 are enriched in ErbB2+ cell lines.
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Figure 2. 
ErbB2 is incapable of maintaining a tumorigenic state. (A) Doxycycline-inducible NMuMG 
cells (NMuMG-iSP) rapidly express ErbB2ΔEx16 in the presence of doxycycline within 24 
hours of induction. (B) In cells expressing stable ErbB2 with inducible ErbB2ΔEx16 
(NMuMG-WTiSP), quantitative PCR confirms robust expression of ErbB2ΔEx16 mRNA in 
the presence, but not the absence of doxycycline. By contrast, ErbB2 expression remains 
constant. (C) When NMuMG-WTiSP cells were injected orthotopically into athymic nude 
mice, tumors were detected 3 weeks after injection when treated with doxycycline. (D) 
Withdrawal of doxycycline results in rapid and complete regression of the WTiSP tumors.
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Figure 3. 
ErbB2ΔEx16 displays altered internalization, which affects response to therapy. (A) Serum-
induced internalization of NeuNT results in co-localization with EEA1, which is absent in 
ErbB2ΔEx16 cells. (B) Quantification of a biotin internalization assay (C) reveals that while 
NeuNT is effectively internalized, ErbB2ΔEx16 remains at the cell surface. (D) Treatment of 
NMuMG-ErbB2ΔEx16 cells with the anti-ErbB2 therapy T-DM1 reveals an innate 
resistance to treatment compared to SkBR3 cells, which express very high levels of full 
length ErbB2. Additionally, (E) NMuMG cells expressing full length ErbB2 are intrinsically 
more sensitive to T-DM1 treatment than NMuMGErbB2ΔEx16 cells.
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Figure 4. 
A transgenic mouse model of ErbB2ΔEx16-driven tumorigenesis. (A) A reverse 
tetracycline-dependent transactivator (rtTA) is expressed in the mammary epithelium of 
transgenic mice via the MMTV promoter. In the presence of doxycycline, ErbB2ΔEx16 is 
expressed in mammary epithelial cells through rtTA binding to the tetracycline-dependent 
promoter (TetO). (B) Expression of ErbB2ΔEx16 drives rapid tumor onset with a latency of 
28 and 10 days for two independent founder lines, compared to 280 days for full length 
ErbB2. (C) ErbB2 and ErbB2ΔEx16 models metastasize to the lungs with a frequency of 
74% and 95%, respectively, with (D) a significantly increased number of lung lesions in 
ErbB2ΔEx16 mice (p=0.03).
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Figure 5. 
Histopathology of ErbB2-driven tumor phenotypes described by hematoxylin and eosin 
stained slides (A and C) and comparing the relative amounts of ECM deposition using green 
trichrome staining for connective tissue (B and D). Figures 1A and 1B illustrate a signature 
solid nodular tumor from an ErbB2 bearing mouse. In contrast, Panels C and D illustrates 
the more glandular phenotype induced by the ErbB2ΔEx16 protein, which has abundant 
connective tissue separating the nests and cords of tumor cells. These tumors infiltrate 
through the adipose tissue and do not have pushing margins seen in the signature phenotype 
(Panels A and B). The scale bar indicates 250 microns (Panel A).
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Figure 6. 
Immunoblot analysis of ErbB2-expressing tumors. (A) Full length ErbB2-driven tumors co-
express heterodimer partners ErbB3 and EGFR, whereas ErbB2ΔEx16 tumors arise in the 
absence of heterodimerization partners. (B) ErbB2ΔEx16 displays heightened activation of 
Src-family kinases (SFK) and p38 MAPK. (C) Additionally, ErbB2ΔEx16-expressing 
tumors preferentially activate a distinct subset of transcription factors, primarily Smad2, 
HIF1α, Stat3, and YB1. (D) Unsupervised hierarchical clustering of tumors results in 
grouping of tumors by genotype.
Turpin et al. Page 23
Oncogene. Author manuscript; available in PMC 2016 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. 
Analysis of transcription factor activation from gene expression profiling. (A) Downstream 
of ErbB2ΔEx16, the transcription factors Smad2, Stat3, and Hif1α are preferentially 
activated, as evidenced by enrichment in known target gene expression obtained from gene 
expression profiling. Enrichment plots by GSEA (B and D) suggest strong association of 
Smad2 (p=0.0019) and HIF1α (p=0.014) with ErbB2ΔEx16 expression. (C) Activity of the 
Stat3 transcriptional networks is also is enriched in ErbB2ΔEx16-expressing tumors 
(p=0.008).
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